

Elevated levels of Alanine Transaminase (ALT) is an independent risk factor for Coronary Artery Disease (CAD)

TANVIR AHMAD BHATTI, SYED MUHAMMAD AFTAB HASSAN, WASIM ASHRAF, ASAD JAMIL AWANS, SADAF ZAHRA SYED

Department of Cardiology, Mayo Hospital, Lahore

Correspondence to Dr. Tanvir Ahmad Bhatti, Email: dtanvir@yahoo.com, Cell: 03334295547

ABSTRACT

Background: Coronary artery disease is the most common form of heart disease with multifactorial etiology and atherosclerosis. Recently it is considered that ALT associated with endothelial dysfunction and carotid atherosclerosis. The predictive value of ALT for coronary events seems independent of traditional risk factors and the features of the metabolic syndrome.

Aim: To find out association of elevated ALT with coronary artery disease

Methods: This cross sectional study was carried out on 100 patients presented with clinically suspected CAD. Serum ALT was measured. Patients underwent angiography and images of coronary arteries were obtained and presence of CAD was noted. Relative risk was calculated to measure association between raised ALT and CAD.

Results: The mean age range of patients was 49.16 ± 10.15 years. There were 78 male and 22 female patients. The male to female ratio was 3.54:1. The mean ALT was 41.58 ± 16.18 U/L. Coronary angiography findings showed that 29% patients had normal coronaries, 4% had mild CAD, 49% had moderate CAD and 18% had severe CAD. There were 1.8 times high risk of CAD in patients with raised ALT.

Conclusion: It is concluded that although difference in CAD and raised ALT is insignificant but the risk of CAD is 1.8 times high in patients with raised ALT.

Keywords: Coronary Artery Diseases, Serum Alanine Transaminase

INTRODUCTION

Coronary Artery Disease (CAD) is the most common form of heart disease with multifactorial etiology and atherosclerosis is its most common cause. Atherosclerosis is caused by obstruction of the coronary arteries by atheromatous plaque. It is the commonest cause of cardiovascular disability and death and includes chronic (stable) angina, unstable angina, Prinzmetal (variant) angina, microvascular angina and acute myocardial infarction. Syndromes of CAD also occur in the form of asymptomatic (silent) myocardial ischemia, congestive heart failure, cardiac arrhythmias and sudden death^{1,2}.

Eighty percent of the deaths due to these diseases and 86% of the global burden of cardiac disease are in the developing countries including Pakistan.² In Pakistan the prevalence of ACS is increasing rapidly with definite diagnosis in men than in women (6.1% vs 4.0%; $p=0.009$)^{3,4}. The World Health Organization (WHO) has estimated that by 2020, the global number of deaths from CAD will have risen from 7.2 million in 2002 to 11.1 million^{5,6}.

It is now well known that development of insulin resistance results in increased hepatic gluconeogenesis and overproduction of triglyceride-rich lipoproteins and consequently nonalcoholic fatty liver disease (NAFLD) and is associated with central obesity, type 2 diabetes and dyslipidaemia⁷. The correlation of liver transaminases with blood pressure, dyslipidaemia, blood glucose and waist circumference as components of the metabolic syndrome have been suggested in several studies⁸.

Besides prior reports, recent evidence of the association between hepatic steatosis or its marker alanine

aminotransferase (ALT) and endothelial dysfunction, carotid atherosclerosis and coronary events substantiates the probable predictive value of liver enzymes for CAD; however, this has not been directly and quantitatively investigated before, specially here in Pakistan^{9,10,11}.

The objective of the study was to find out association of elevated ALT with coronary artery disease

MATERIAL AND METHODS

This cross sectional study was conducted in the Department of Cardiology, Mayo Hospital Lahore for a period of two years.

Sample size: 100 patients presenting with clinically suspected CAD.

Inclusion criteria: Age 18-70 years of either gender presenting with clinically suspected CAD

Exclusion criteria: Excessive alcohol intake, cancer, rheumatoid arthritis, chronic kidney disease, hepatotoxic drugs, inflammatory bowel disease, acute myocardial infarction, already known CAD.

Data collecting procedure: All patients who were clinically suspected CAD were enrolled from OPD and from cath lab after an informed consent. Baseline demographic information such as age, sex, weight, height, education and address were noted. History of chest pain and shortness of breath with his/her functional class were noted along with examination. Routine laboratory tests were done. Serum ALT were measured on fresh samples according to the methods of the International Federation of Clinical Chemistry. Then angiographic assessments were performed according to Judkin's method with a digital angiographic system. Stenosis score (0-3 points; number and severity of coronary stenosis or lesions; 0 for Normal, 1 for coronary lesion with diameter stenosis <50%, 2 for 50-75% and 3 for >75% diameter stenosis was noted.

Received on 07-10-2019

Accepted on 27-04-2020

Statistical analysis: Data entry and analysis was done by using SPSS 15.0 Quantitative variables were presented with mean±SD. Qualitative variables were presented by using frequency, percentage and appropriate graphs. Relative risk was calculated to measure association between CAD and raised ALT. RR>1 was considered as risk of association with p-value≤0.05 was considered as significant.

RESULTS

Table 1: Baseline characteristics of patients (n=100)

Characteristic	No. of Patients
Age	49.16±10.15years
Gender (Male / Female)	78 / 22
BMI (kg/m ²)	26.51±2.32
ALT (U/L)	41.58±16.18

Table 2: Distribution of raised ALT

ALT (10-40)	81 (81%)
ALT (>40)	19 (19%)
Total	100 (100%)

Fig 1: Distribution of CAD on angiography




Table 3: Association of raised ALT with CAD

AAS SCORE	ALT Level		Total
	10-40	>40	
AAS score 0= Non CAD	27	2	29
AAS score 1-9 = CAD	62	9	71
AAS score 1-3 = Mild CAD	4	0	4
AAS score 4-6= Moderate CAD	43	6	49
AAS score 7-9= Severe CAD	15	3	18
Total	89	11	100

Chi-Square test= 6.629, p-value= 0.356 (Insignificant)
Relative risk = 1.838 (95% CI; 0.4226, 7.994)

The mean age of patients was 49.16±10.15years. Out of total 100 patients, 78 males and 22 female with male to female ratio 3.54:1. The mean BMI was 26.51±2.32kg/m². The mean ALT was 41.58±16.18 U/L. (Table 1) There were 81 patients with normal ALT while 19 patients had raised ALT. (Table 2) On angiography, CAD was found in 71% patients while CAD was absent in 29% cases (Fig 1). Among 100 patients 29 had no CAD (AAS score 0) but 71 had CAD (AAS score 1-9). Among patients with CAD, 4

had AAS score 1-3 (Mild CAD), 49 had AAS score 4-6 (Moderate CAD) and 18 had AAS score 7-9 (Severe CAD) (Table 3).

DISCUSSION

Associations between elevated serum levels of liver enzymes and increased cardiovascular risk have attracted much interest. In fact, serum ALT have shown to predict cardiovascular events in prospective studies independently from conventional cardiovascular risk factors.¹¹⁻¹⁴ The most frequent cause of elevated liver enzymes in current clinical practice is non-alcoholic fatty liver disease, which affects as much as 15–20% of the general population and up to 90% of patients with type 2 diabetes^{15,16}.

Pathophysiologically, NAFLD is strongly related to insulin resistance and to the metabolic syndrome, the cluster of cardiovascular risk factors associated with insulin resistance.¹⁷ Indeed, elevated GGT is a predictor of incident of metabolic syndrome.¹⁸ Both insulin resistance and the clinical entity of the metabolic syndrome predict vascular events; it is a matter of debate in as far elevated liver enzymes are associated with cardiovascular events independent of the clinical diagnosis of the metabolic syndrome.¹⁹ Myocardial infarction, a frequently applied endpoint in clinical studies, does not optimally reflect the atherogenicity of metabolic parameters. It is the last step in the development of atherothrombotic CAD, and thrombogenic factors ultimately determine whether or not infarction occurs²⁰.

Hardly any data on the association between liver enzymes and angiographically determined coronary artery disease is available from the literature. A single small study from Iran, while failing to show an association between liver enzymes and coronary atherosclerosis in the total study population, described an association of liver enzymes with severe CAD in the subgroup of women only; formal interaction analyses were not performed in this study.²¹ According to the results of a study in their larger population of angiographically characterized patients, they neither among women nor among men observed an association between liver enzymes and coronary atherosclerosis. Further, interaction analyses in their investigation did not suggest a significant gender difference with respect to the association between liver enzymes and coronary atherosclerosis²².

The association of elevated liver enzymes with the angiographically determined coronary artery state is uncertain in literature. In the present study we therefore aimed at investigating the associations of ALT with angiographically determined CAD. The correlation of liver transaminases with blood pressure, dyslipidaemia, blood glucose and waist circumference as components of the metabolic syndrome have been suggested in several studies.²³⁻²⁵ Besides prior reports, recent evidence of the association between hepatic steatosis or its marker ALT and endothelial dysfunction, carotid atherosclerosis and coronary events substantiates the probable predictive value of liver enzymes for CAD; however, this has not been directly and quantitatively investigated before^{11,24,25}.

More recently, Schindhelm et al¹¹ in a prospective study suggested that ALT predicts coronary events. It is

noteworthy that prior studies have shown that the association between the metabolic syndrome and nonfatal CAD is somewhat stronger in women than in men. Conversely, cardiovascular events more often have a fatal outcome in men.²⁶ Given that European guidelines for risk stratification are merely based on risk of fatal CVD²⁷, further prospective studies are needed to elucidate the actual role of liver transaminases in predicting cardiovascular morbidity and mortality. There is a growing body of evidence in support of the association of elevated ALT with insulin resistance and various components of the metabolic syndrome, namely type 2 diabetes, which is considered to be a major risk factor for atherosclerosis^{24,25}.

CONCLUSION

It is concluded that although difference in CAD and raised ALT is insignificant but the risk of CAD is 1.8 times high in patients with raised ALT. But further studies are required to confirm the evidence with large sample size and proper case control or cohort studies are required to confirm the association.

REFERENCES

- Angulo P. Nonalcoholic fatty liver disease. *New England Journal of Medicine* 2002;346(16):1221-31.
- Abbas S, Kitchlew A, Abbas S. Disease burden of Ischemic Heart Disease in Pakistan and its risk factors. *Ann Pak Inst Med Sci* 2009;5(3):145-50.
- Zaidi B, Zaidi A, Zahir J, Khar B, Murad F, Hussain T. Risk Factors and the Presenting Symptoms Among Young Males with Acute Coronary Syndrome. *Journal of Rawalpindi Medical College (JRMC)* 2012;16(2):87-9.
- Jafar TH, Qadri Z, Chaturvedi N. Coronary artery disease epidemic in Pakistan—more electrocardiographic evidence of ischemia in women than in men. *Heart* 2007.
- Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001;50(8):1844-50.
- Bruckert E, Giral P, Ratzu V, Poynard T, Chapman M, Opolon P, et al. A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients. *Metabolism—Clinical and Experimental* 2002;51(8):1071-6.
- Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. *Diabetes* 2005;54(11):3140-7.
- Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Kempf J, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes* 2004;53(10):2623-32.
- Schindhelm RK, Diamant M, Bakker SJ, Van Dijk RA, Scheffer PG, Teerlink T, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. *European journal of clinical investigation* 2005;35(6):369-74.
- Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. *Arteriosclerosis, thrombosis, and vascular biology* 2005;25(5):1045-50.
- Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. *Atherosclerosis* 2007;191(2):391-6.
- Ruttman E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. γ -Glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163 944 Austrian adults. *Circulation* 2005;112(14):2130-7.
- Meisinger C, Döring A, Schneider A, Löwel H. Serum γ -glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. *Atherosclerosis* 2006;189(2):297-302.
- Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. *The Journal of Clinical Endocrinology & Metabolism* 2005;90(10):5698-703.
- Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *New England journal of medicine* 1992;326(4):242-50.
- Adibi P, Sadeghi M, Mahsa M, Rozati G, Mohseni M. Prediction of coronary atherosclerotic disease with liver transaminase level. *Liver International* 2007;27(7):895-900.
- Saely CH, Vonbank A, Rein P, Woess M, Beer S, Aczel S, et al. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. *Clinica Chimica Acta* 2008;397(1-2):82-6.
- Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *The lancet* 2005;365(9468):1415-28.
- Seppälä-Lindroos A, Vehkavaara S, Häkkinen A-M, Goto T, Westerbacka J, Sovijärvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. *The Journal of Clinical Endocrinology & Metabolism* 2002;87(7):3023-8.
- Adiels M, Taskinen M-R, Packard C, Caslake M, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. *Diabetologia* 2006;49(4):755-65.
- Targher G, Bertolini L, Scala L, Poli F, Zenari L, Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. *Clinical endocrinology* 2004;61(6):700-3.
- Browning JD, Szczepaniak LS, Dobbins R, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004;40(6):1387-95.
- Conroy R, Pyörälä K, Fitzgerald Ae, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *European heart journal* 2003;24(11):987-1003.
- Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. *Arteriosclerosis, thrombosis, and vascular biology* 2005;25(1):193-7.
- Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. *Hepatology* 2002;35(4):898-904.
- Gianturco SH, Bradley WA, editors. Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia. *Seminars in thrombosis and hemostasis*; 1988.
- Conroy R, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *European heart journal* 2003;24(11):987-1003.